STABLE DOSAGE FORM OF ETIDRONATE-CYTARABINE CONJUGATE
The invention relates to the field of medicine and pharmaceuticals and particularly to a novel dosage form of an antitumor preparation, which ensures the hydrolytic and physical stability of said preparation, as well as to a method for producing a dosage form of this type. The stable dosage form is...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
09.08.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention relates to the field of medicine and pharmaceuticals and particularly to a novel dosage form of an antitumor preparation, which ensures the hydrolytic and physical stability of said preparation, as well as to a method for producing a dosage form of this type. The stable dosage form is a lyophilizate comprising an etidronate-cytarabine conjugate or a pharmaceutically acceptable salt thereof, and a stabilizer, which is a divalent metal salt, in a molar ratio of stabilizer to conjugate of 1:1 to 20:1. A dosage form of this type ensures the hydrolytic and physical stability of the conjugate during long-term storage, and the stability of solutions of the conjugate for parenteral administration during clinical use. |
---|---|
Bibliography: | Application Number: EP20160871137 |